Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone

Contraception

Volumn 74, Issue 6, 2006, Pages 451-457

  Ahrendt, Hans Joachim ^a   Nisand, Israel ^b   Bastianelli, Carlo ^c   Gómez, Maria Angeles ^d   Gemzell Danielsson, Kristina ^e   Urdl, Wolfgang ^f   Karskov, Birgit ^a   Oeyen, Luc ^g   Bitzer, Johannes ^h   Page, Geert ^a   Milsom, Ian ⁱ  

^a Hautepierre Hospital ^*  (Belgium)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Valencian Health Agency   (Spain)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g Sint Vincentiusziekenhuis   (Belgium)

^h UNIVERSITY OF BASEL   (Switzerland)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Compliance; Contraceptive; Efficacy; NuvaRing; Pill; Tolerability

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL;

ABDOMINAL PAIN; ADULT; ARTICLE; CHOLELITHIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HUMAN; LEUKORRHEA; MASTALGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; INTRAUTERINE DEVICES; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREGNANCY; PROGESTERONE CONGENERS; TREATMENT OUTCOME;

EID: 33845986347     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.07.004     Document Type: Article

References (15)

1. Rosenberg M.J., and Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 179 (1998) 577-582
2. Rosenberg M.J., Waugh M.S., Burnhill M.S. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect. 1998;30:89-92,104.
3. Rosenberg M., and Waugh M.S. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 180 (1999) S276-S279
4. Burkman R.T. Oral contraceptives: current status. Clin Obstet Gynecol 44 (2001) 62-72
5. Timmer C.J., and Mulders T.M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 39 (2000) 233-242
6. Roumen F.J., Apter D., Mulders T.M., and Dieben T.O. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16 (2001) 469-475
7. Dieben T.O., Roumen F.J., and Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 100 (2002) 585-593
8. Oddsson K., Leifels-Fischer B., de Melo N.R., et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71 (2005) 176-182
9. Bjarnadottir R.I., Tuppurainen M., and Killick S.R. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 186 (2002) 389-395
10. Ahrendt H.-J., Nap M.A., and Marintcheva-Petrova M.Z. Contraceptive efficacy with NuvaRing vs two combined oral contraceptives - data from a pooled analysis. Eur J Contraception Reprod Health Care 11 Suppl 1 (2006) 59
11. Urdl W., Apter D., Alperstein A., Koll P., et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol 121 (2005) 202-210
12. Archer D.F., Cullins V., Creasy G.W., and Fisher A.C. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 69 (2004) 189-195
13. Novak A., de la Loge C., Abetz L., and van der Meulen E.A. The combined contraceptive vaginal ring, NuvaRing®: an international study of user acceptability. Contraception 67 (2003) 187-194
14. Rosenberg M.J., Meyers A., and Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 60 (1999) 321-329
15. Rosenberg M.J., Waugh M.S., and Meehan T.E. Use and misuse of oral contraceptives: risk indicators for poor pill-taking and discontinuation. Contraception 51 (1995) 283-288